At the time of writing, Castle Biosciences Inc [CSTL] stock is trading at $22.28, down -3.30%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CSTL shares have gain 5.79% over the last week, with a monthly amount glided 4.85%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Castle Biosciences Inc [NASDAQ: CSTL] stock has seen the most recent analyst activity on December 14, 2023, when Guggenheim initiated its Buy rating and assigned the stock a price target of $25. Previously, Scotiabank started tracking the stock with Sector Outperform rating on January 05, 2023, and set its price target to $54. On January 07, 2022, Stephens initiated with a Overweight rating and assigned a price target of $59 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $94 on April 30, 2021. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $70 as its price target on November 10, 2020. Canaccord Genuity reiterated a Buy rating for this stock on December 27, 2019, and upped its price target to $35. In a note dated August 19, 2019, SVB Leerink initiated an Outperform rating and provided a target price of $28 on this stock.
For the past year, the stock price of Castle Biosciences Inc fluctuated between $12.07 and $25.91. Currently, Wall Street analysts expect the stock to reach $41 within the next 12 months. Castle Biosciences Inc [NASDAQ: CSTL] shares were valued at $22.28 at the most recent close of the market. An investor can expect a potential return of 84.02% based on the average CSTL price forecast.
Analyzing the CSTL fundamentals
According to Castle Biosciences Inc [NASDAQ:CSTL], the company’s sales were 250.72M for trailing twelve months, which represents an 73.59% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.12%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.08 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.42 points at the first support level, and at 20.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.95, and for the 2nd resistance point, it is at 23.63.
Ratios To Look Out For
It is important to note that Castle Biosciences Inc [NASDAQ:CSTL] has a current ratio of 9.25. Further, the Quick Ratio stands at 9.02, while the Cash Ratio is 2.6. Considering the valuation of this stock, the price to sales ratio is 2.45, the price to book ratio is 1.53.
Transactions by insiders
Recent insider trading involved Stokes Frank, Officer, that happened on Aug 07 ’24 when 10000.0 shares were purchased. Chief Operating Officer, Oelschlager Kristen M completed a deal on Jul 29 ’24 to sell 2793.0 shares. Meanwhile, Chief Operating Officer Oelschlager Kristen M sold 2793.0 shares on Jul 01 ’24.
